IconOVir Bio Employee Directory
Biotechnology ResearchCalifornia, United States2-10 Employees
IconOVir Bio is a preclinical-stage biotechnology company focused on cancer therapy using oncolytic viruses. Its platform builds on technology developed by Clodagh O’Shea, Ph.D., at the Salk Institute, with the aim of addressing limitations observed in earlier generations of oncolytic virus therapies. The company is based in San Diego, California, and operates in the biotechnology research sector with a small team. Its lead program, ICVB-1042, has progressed from preclinical validation to early clinical testing, with proof-of-concept disclosed in 2022 and the first patient dosed in a Phase 1 trial in 2023. The company targets oncology researchers and potential collaborators seeking novel virotherapy options to improve cancer treatment. Through its proprietary platform, IconOVir Bio aims to advance the development of oncolytic virus therapy in oncology.